Compare · BIB vs HCXY
BIB vs HCXY
Side-by-side comparison of ProShares Ultra Nasdaq Biotechnology (BIB) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIB and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.43B.
- HCXY has hit the wire 4 times in the past 4 weeks while BIB has been quiet.
BIB
ProShares Ultra Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest BIB
Latest HCXY
- Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.
- Hercules Capital Announces Date for Release of Third Quarter 2026 Financial Results and Conference Call
- Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029
- Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029
- Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors
- Hercules Capital’s Investment Adviser Surpasses $2.3 Billion in Investable Capital
- Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031